Breast Cancer Research and Treatment

, Volume 141, Issue 3, pp 495–505 | Cite as

Multivitamin and mineral use and breast cancer mortality in older women with invasive breast cancer in the women’s health initiative

  • S. Wassertheil-Smoller
  • A. P. McGinn
  • N. Budrys
  • R. Chlebowski
  • G. Y. Ho
  • K. C. Johnson
  • D. S. Lane
  • W. Li
  • M. L. Neuhouser
  • J. Saquib
  • J. M. Shikany
  • Y. Song
  • C. Thomson
Epidemiology

Abstract

Multivitamin use is common in the United States. It is not known whether multivitamins with minerals supplements (MVM) used by women already diagnosed with invasive breast cancer would affect their breast cancer mortality risk. To determine prospectively the effects of MVM use on breast cancer mortality in postmenopausal women diagnosed with invasive breast cancer, a prospective cohort study was conducted of 7,728 women aged 50–79 at enrollment in the women’s health initiative (WHI) in 40 clinical sites across the United States diagnosed with incident invasive breast cancer during WHI and followed for a mean of 7.1 years after breast cancer diagnosis. Use of MVM supplements was assessed at WHI baseline visit and at visit closest to breast cancer diagnosis, obtained from vitamin pill bottles brought to clinic visit. Outcome was breast cancer mortality. Hazard ratios and 95 % confidence intervals (CIs) for breast cancer mortality comparing MVM users to non-users were estimated using Cox proportional hazard regression models. Analyses using propensity to take MVM were done to adjust for potential differences in characteristics of MVM users versus non-users. At baseline, 37.8 % of women reported MVM use. After mean post-diagnosis follow-up of 7.1 ± 4.1 (SD) years, there were 518 (6.7 %) deaths from breast cancer. In adjusted analyses, breast cancer mortality was 30 % lower in MVM users as compared to non-users (HR = 0.70; 95 % CI 0.55, 0.91). This association was highly robust and persisted after multiple adjustments for potential confounding variables and in propensity score matched analysis (HR = 0.76; 95 % CI 0.60–0.96). Postmenopausal women with invasive breast cancer using MVM had lower breast cancer mortality than non-users. The results suggest a possible role for daily MVM use in attenuating breast cancer mortality in women with invasive breast cancer but the findings require confirmation.

Keywords

Breast cancer Multivitamins Vitamins Women’s health initiative WHI Breast cancer mortality 

References

  1. 1.
    Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF (2004) Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 160(4):339–349PubMedCrossRefGoogle Scholar
  2. 2.
    Velicer CM, Ulrich CM (2008) Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol 26(4):665–673PubMedCrossRefGoogle Scholar
  3. 3.
    Neuhouser ML, Wassertheil-Smoller S, Thomson C, Aragaki A, Anderson GL, Manson JE, Patterson RE, Rohan TE, van Horn L, Shikany JM et al (2009) Multivitamin use and risk of cancer and cardiovascular disease in the Women’s Health Initiative cohorts. Arch Intern Med 169(3):294–304PubMedCrossRefGoogle Scholar
  4. 4.
    Park SY, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN (2011) Multivitamin use and the risk of mortality and cancer incidence: the multiethnic cohort study. Am J Epidemiol 173(8):906–914PubMedCrossRefGoogle Scholar
  5. 5.
    Chan AL, Leung HW, Wang SF (2011) Multivitamin supplement use and risk of breast cancer: a meta-analysis. Ann Pharmacother 45(4):476–484PubMedCrossRefGoogle Scholar
  6. 6.
    Mursu J, Robien K, Harnack LJ, Park K, Jacobs DR Jr (2011) Dietary supplements and mortality rate in older women: the Iowa Women’s Health Study. Arch Intern Med 171(18):1625–1633PubMedCrossRefGoogle Scholar
  7. 7.
    Nechuta S, Lu W, Chen Z, Zheng Y, Gu K, Cai H, Zheng W, Shu XO (2011) Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 20(2):262–271PubMedCrossRefGoogle Scholar
  8. 8.
    Kwan ML, Greenlee H, Lee VS, Castillo A, Gunderson EP, Habel LA, Kushi LH, Sweeney C, Tam EK, Caan BJ (2011) Multivitamin use and breast cancer outcomes in women with early-stage breast cancer: the life after cancer epidemiology study. Breast Cancer Res Treat 130(1):195–205PubMedCrossRefGoogle Scholar
  9. 9.
    Fleischauer AT, Simonsen N, Arab L (2003) Antioxidant supplements and risk of breast cancer recurrence and breast cancer-related mortality among postmenopausal women. Nutr Cancer 46(1):15–22PubMedCrossRefGoogle Scholar
  10. 10.
    Saquib J, Rock CL, Natarajan L, Saquib N, Newman VA, Patterson RE, Thomson CA, Al-Delaimy WK, Pierce JP (2011) Dietary intake, supplement use, and survival among women diagnosed with early-stage breast cancer. Nutr Cancer 63(3):327–333PubMedCrossRefGoogle Scholar
  11. 11.
    Greenlee H, Kwan ML, Kushi LH, Song J, Castillo A, Weltzien E, Quesenberry CP Jr, Caan BJ (2012) Antioxidant supplement use after breast cancer diagnosis and mortality in the life after cancer epidemiology (LACE) cohort. Cancer 118(8):2048–2058PubMedCrossRefGoogle Scholar
  12. 12.
    Lesperance ML, Olivotto IA, Forde N, Zhao Y, Speers C, Foster H, Tsao M, MacPherson N, Hoffer A (2002) Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. Breast Cancer Res Treat 76(2):137–143PubMedCrossRefGoogle Scholar
  13. 13.
    Group TWS (1988) Design of the Women’s Health Initiative clinical Trial and Observational Study. Control Clin Trials 19:61–109Google Scholar
  14. 14.
    Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M et al (2003) Outcomes ascertainment and adjudication methods in the Women’s Health Initiative. Ann Epidemiol 13(9 Suppl):S122–S128PubMedCrossRefGoogle Scholar
  15. 15.
    Burnam M, Wells KB, Leake B, Landsverk J (1988) Development of a brief screening instrument for detecting depressive disorders. Med Care 26:775–789PubMedCrossRefGoogle Scholar
  16. 16.
    Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1(3):385–401CrossRefGoogle Scholar
  17. 17.
    Robins LN, Helzer JE, Croughan J, Ratcliff KS (1981) National institute of mental health diagnostic interview schedule: its history, characteristics, and validity. Arch Gen Psychiatry 38:381–389PubMedCrossRefGoogle Scholar
  18. 18.
    Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483PubMedCrossRefGoogle Scholar
  19. 19.
    Velentzis LS, Keshtgar MR, Woodside JV, Leathem AJ, Titcomb A, Perkins KA, Mazurowska M, Anderson V, Wardell K, Cantwell MM (2011) Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study. Breast Cancer Res Treat 128(2):473–482PubMedCrossRefGoogle Scholar
  20. 20.
    Greenlee H, Hershman DL, Jacobson JS (2009) Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Res Treat 115(3):437–452PubMedCrossRefGoogle Scholar
  21. 21.
    Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, Unger JM, Budd GT, Hershman DL, Moore HC et al (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137(3):903–913PubMedCrossRefGoogle Scholar
  22. 22.
    Sotgia F, Martinez-Outschoorn UE, Lisanti MP (2011) Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? BMC Med 9:62PubMedCrossRefGoogle Scholar
  23. 23.
    Premkumar VG, Yuvaraj S, Sathish S, Shanthi P, Sachdanandam P (2008) Anti-angiogenic potential of Coenzyme Q10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul Pharmacol 48(4–6):191–201PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • S. Wassertheil-Smoller
    • 1
  • A. P. McGinn
    • 1
  • N. Budrys
    • 2
  • R. Chlebowski
    • 3
  • G. Y. Ho
    • 1
  • K. C. Johnson
    • 4
  • D. S. Lane
    • 5
  • W. Li
    • 6
  • M. L. Neuhouser
    • 7
  • J. Saquib
    • 8
  • J. M. Shikany
    • 9
  • Y. Song
    • 10
  • C. Thomson
    • 11
  1. 1.Department of Epidemiology and Population HealthAlbert Einstein College of MedicineBronxUSA
  2. 2.Department of Obstetrics and GynecologyUniversity of Oklahoma Health Science CenterOklahoma CityUSA
  3. 3.Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterTorranceUSA
  4. 4.Department of Preventive MedicineUniversity of Tennessee Health Science CenterMemphisUSA
  5. 5.Department of Preventive MedicineStony Brook University School of MedicineStony BrookUSA
  6. 6.Division of Preventive and Behavioral MedicineUniversity of Massachusetts Medical SchoolWorcesterUSA
  7. 7.Division of Public Health SciencesFred Hutchinson Cancer Research CenterSeattleUSA
  8. 8.Stanford Prevention Research CenterStanford UniversityStanfordUSA
  9. 9.Division of Preventive Medicine, School of MedicineUniversity of Alabama at BirminghamBirminghamUSA
  10. 10.Division of Preventive MedicineBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  11. 11.Zuckerman College of Public HealthUniversity of Arizona Cancer CenterTucsonUSA

Personalised recommendations